We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
CEM Corporation Sells 100th Automated Peptide Synthesizer
News

CEM Corporation Sells 100th Automated Peptide Synthesizer

CEM Corporation Sells 100th Automated Peptide Synthesizer
News

CEM Corporation Sells 100th Automated Peptide Synthesizer

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CEM Corporation Sells 100th Automated Peptide Synthesizer"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CEM Corporation has announced that the Company has recently sold its 100th automated microwave peptide synthesizer in only 2 years time.

The Liberty™ Microwave Peptide Synthesizer was first introduced in February 2005. It has quickly become the most preferred peptide synthesizer available due to the benefits of microwave technology, and is being used by many well-known research facilities and companies including Scripps Research Institute, St. Jude Children’s Research Hospital, Hoffman LaRoche, University of Edinburgh (UK), Rockefeller University, Amgen, Mayo Clinic, and Kyoto University (Japan).

Additionally, CEM has sold 40 of its Discover®SPS Systems, a manual version of the microwave peptide synthesizer. The use of microwave energy for solid-phase peptide synthesis allows peptides to be synthesized faster, often with higher purities than can be produced using traditional methods.

“We have seen a great acceptance of microwave systems in the peptide synthesis community, because they give biochemists the ability to perform new syntheses and do other things that simply weren’t possible using conventional methods," said Michael J. Collins, president and CEO of CEM Corporation. “We expect to see continued growth in this market for the next several years.”

Liberty’s ability to produce difficult peptides that cannot be made using conventional methods gives companies interested in peptide production a definite advantage.

CEM had an article accepted for publication by the Journal of Peptide Science due out next month. The article features additional research that has further optimized the technology. This is part of CEM's continued mission to provide instrumentation and leading-edge application and chemistry support.

Advertisement